SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh strong financial results and aggressive growth targets against concerns over potential share offerings and broader software sector weakness. While many remain bullish on the company's AI-driven ad engine and cash flow, traders are actively discussing the stock's unpredictable price swings and high-stakes positioning ahead of upcoming catalyst events.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing intense volatility as investors weigh strong international growth and record revenue against concerns over brand momentum and competitive pressures ahead of its upcoming earnings report. The community is actively debating whether the recent share price slide near 52-week lows represents a deliberate institutional accumulation phase or a signal of fundamental weakness.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and a sharp price correction as the market weighs competitive pressures from new AI agent technologies against the company's long-term infrastructure potential. Investors are actively debating whether this pullback represents a major fundamental breakdown or an overreaction that offers a strategic buying opportunity for the edge computing leader.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant leadership overhaul that replaced the former CEO with Chairman Kevin Tang, sparking optimism for a potential buyout. The community is actively debating the strategic implications of Tangs aggressive management style and the company's recent acquisition of Kezar Life Sciences as key catalysts for future value creation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors react to a significant data center campus development in Thailand and an expanded partnership with Yotta, fueling speculation about long-term revenue potential and a possible short squeeze due to high short interest and a limited tradable float. The community is actively debating the legitimacy of these massive contract announcements and the company's ability to finance them, with many longs expressing high conviction in the stock's future as it attempts to break through key technical resistance levels.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is currently trending following a report identifying the company as a key stealth supplier for Nvidia and Apple's advanced optical infrastructure, specifically regarding wafer-level optics for Co-Packaged Optics. The community is actively debating the sustainability of this price action, with some investors pointing to long-term growth in AI data center components, while skeptics caution against potential volatility and speculative hype.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is heading into earnings with heightened volatility as investors weigh the company's path to profitability and potential AI-driven ad performance against concerns over executive leadership and stagnant North American user growth. While the community is divided between those betting on a turnaround through cost-cutting and potential buyout interest, others are actively preparing for typical post-earnings swings, debating if the stock is a deep-value opportunity or a long-term trap.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility as investors weigh strong fundamental performance and profitability against intense short-interest and broader macro uncertainty. While the community is actively discussing the stock's potential for a massive re-rating driven by its AI underwriting model and recent institutional wins, the price action remains heavily influenced by speculative trading and regional geopolitical concerns affecting the broader fintech sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors weigh strong demand for its high-energy silicon anode battery technology against ongoing volatility driven by warrant redemption mechanics. Community discussion is focused on the company's expanding order backlog in the defense and electric mobility sectors, with many traders closely monitoring whether the share price can maintain the critical support levels required to trigger warrant exercises.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following the sale of its SDX portfolio for $50 million and the full repayment of its $63 million term loan, moves that have significantly de-risked the balance sheet and eliminated long-standing litigation overhang. Investors are actively discussing whether this financial cleanup serves as a strategic precursor to an imminent buyout, while others remain focused on upcoming catalysts like European regulatory approval and patent extensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FOXO Technologies, Inc. ($FOXO) stock jumped about 58% on Thursday after the Minneapolis, Minnesota-based epigenetic biomarkers technology solutions company confirmed the schedule for its special meeting of shareholders.The company said in a release that the virtual meeting will take place on Friday at 10:30 a.m. ET, as previously announced.The FOXO board requested shareholders vote in favor of the proposals on the proxy card. According to the proxy statement filed with the SEC earlier this month, the company seeks approval for issuing shares equal to or exceeding 20% of its Class A common stock.&nbsp;The company said the common stock would be used to redeem its Series A convertible preferred stock.In mid-December, the company announced a series of&nbsp;capital raising transactions to improve the balance sheet, satisfy minimum stockholders’ equity requirements of the NYSE American exchange and provide capital for growth and reduce outstanding liabilities.These transactions included its subsidiary Renova Health exchanging about $21 million of senior, secured notes issued by it into 21,000 Series A convertible redeemable preferred stock of FOXO. and an institutional investor investing an additional $1 million funding and exchanging $2.2 million debt into 2,464 preferred stock.Seamus Lagan, who was appointed as CEO last month, said, “This meeting will complete the obligations from the acquisition agreements that the Company has completed in recent months."“We look forward to a successful outcome to the meeting and believe the transformation of FOXO in the second half of 2024 creates a new foundation on which we can build a significant and valuable company for the benefit of our shareholders.”<figure class="image"><img style="aspect-ratio:635/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/foxo_sentiment_58c5308c5b.png" alt="foxo-sentiment.png" width="635" height="137"><figcaption>FOXO sentiment and message volume January 16, 2025, as of 11:27 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward FOXA stock improved to ‘extremely bullish’ (97/100), matching the high seen in late-May, from ‘bullish’ a day ago. Message volume also spiked to ‘extremely high’ levels.A retail watcher of the stock on the platform predicted more strength if volume increases.<stembedurl>https://stocktwits.com/HairyBagHolder/message/600418643</stembedurl>Another flagged a buying opportunity, citing technicals.<stembedurl>https://stocktwits.com/ATerragna/message/600397603</stembedurl><a href="https://stocktwits.com/symbol/FOXO">FOXO stock</a> settled Thursday’s session up 57.97% at $0.3150 but fell about 8% in after-hoursFor updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-stock-in-spotlight-following-reports-of-investment-in-drone-startup-muted-analyst-commentary/chGvmwIRnY">Palantir Stock In Spotlight Following Reports Of Investment In Drone Startup, Muted Analyst Commentary: Retail Remains On Sidelines</a>

Nano-Cap FOXO Surges as Retail Frenzy Builds Ahead of Friday’s Special Shareholder Meeting

FOXO seeks approval for issuing shares equal to or exceeding 20% of its Class A common stock. 

Equity

FOXO seeks approval for issuing shares equal to or exceeding 20% of its Class A common stock. 


FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment is involved in research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded on April 27, 2020 and is headquartered in West Palm Beach, FL.

FOXO Technologies Inc - Ordinary Shares - Class A

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

FOXO
FOXO Technologies Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FOXO News

FOXOFOXO Technologies Inc